Going to AAO? Join Us for Free CME In-Person or Virtually
October 18-19, 2024
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
Orasis Pharmaceuticals completes $78 million financing to support commercial launch of Qlosi
According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC Inc. It also has secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing.
Advancing CVI research: NEI initiative and multidisciplinary collaboration
Lotfi Merabet, OD, PhD, MPH, discusses his role as co-chairman of a National Eye Institute initiative focused on advancing research in cerebral visual impairment (CVI). The initiative's key goals include raising awareness about CVI, establishing clear diagnostic criteria, and developing a national registry to track patients and their conditions over time. CVI, a complex condition that affects how the brain processes visual information, requires a multidisciplinary approach involving not only ophthalmologists and optometrists but also neuroscientists, educators, and rehabilitation specialists.
Wilmer Eye Institute receives $10 million donation from James and Heather Gills
The donation will support the development of the Artificial Intelligence Innovation Center, a collaborative hub with a focus of preserving the vision of patients with various eye conditions and eliminating blindness.
Harrow relaunches triamcinolone acetonide injectable suspension
Marketed as Triesence, it is a preservative free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.